PROTHENA PLC (PRTA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for PRTA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PRTA | Director | 68 | ["Scientific expertise in biopharmaceutical research and/or in relevant medical fields", "Experience in the design and implementation of clinical studies in support of drug development", "Experience with regulation in the healthcare industry", "Experience overseeing and driving strategic direction and growth of an organization", "Experience or expertise in financial accounting and reporting processes or the financial management of an organization", "Experience with legal and ethical and public policy issues in the healthcare industry", "Service on a public company board other than Prothena\u2019s", "Experience in capital market transactions or mergers and acquisitions", "Experience in attracting and retaining top talent and building organizational culture"] | ["Compensation Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RARE | Board member and advisor to various life science companies; Independent Chairman | 68 | ["Advisor to various life science companies", "Chairman on the boards of Structure Therapeutics, Inc. and Prothena Corporation plc", "Executive Partner at Sofinnova Ventures", "Chairman, Chief Executive Officer, and President of InterMune, Inc.", "Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc.", "President of the pharmaceutical division of Elan Corporation, plc", "Chairman of the board of directors of Nuvation Bio", "Director on the boards of Intercept Pharmaceuticals, Inc and Seagan Inc.", "B.S. from the University of Miami", "M.B.A. from the University of North Carolina", "Strong operating executive with operational and strategic expertise in the global pharmaceutical market"] | ["Nominating and Corporate Governance Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Daniel G. Welch serves as the chair of the boards of Structure Therapeutics Inc. (since January 2022) and Ultragenyx Pharmaceuticals Inc. (since 2015). He previously served as chair of the board of Nuvation Bio Inc. (from 2020 to September 2024), as a director of SeaGen Inc. (from 2007 until its acquisition by Pfizer in 2023), as chair of the board of AveXis Inc (from 2016 until its acquisition by Novartis in 2018), as a director of Intercept Pharmaceuticals, Inc. (from 2015 to 2020), and as a director of Hyperion Therapeutics (from 2012 until its acquisition by Horizon Pharma in 2015). Prior to these roles he served as an executive partner at Sofinnova Ventures (from 2015 to 2018), as Chief Executive Officer and President of InterMune, Inc. (from 2003 until its acquisition by Roche Holdings in 2014), as chair of the board of InterMune (from 2008 to 2014), as chair of the board and Chief Executive Officer of Triangle Pharmaceuticals, Inc. (from 2002 until its acquisition by Gilead Sciences in 2003), and as President of the pharmaceutical division of Elan Corporation, plc (from 2000 to 2002). Mr. Welch earned his B.A. from the University of Miami and his M.B.A. from the University of North Carolina. He has served on our Board since February 2024 and as Chair of our Board since May 2024. Age: 68 The Board concluded that Mr. Welch should continue to serve as a director given his significant experience serving on the boards of public companies in the pharmaceutical/biotechnology industry. The Board also considered his experience in executive management at several publicly-traded companies in the pharmaceutical/biotechnology industry.